- Country: Slovakia
- Summary: Palivizumab Description: the Subject of the Order is a Human Medicine Called Palivizumab for the Planned Procurement Period of 36 Months. Medical and Technical Specification of the Subject of the Order Palivizumab 50Mg/0.5Ml: • Type Of...
- SKT Ref No: 130303041
- Deadline: 15 Dec 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: EUR 792747
- Notice Type: Tender
- Document Ref. No.: 18171 - MST
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Palivizumab Description: The subject of the contract is a human medicine called Palivizumab for a planned procurement period of 36 months. Medical and technical specification of the subject of the contract Palivizumab 50mg/0.5ml: Type of item: Human medicine Drug + concentration: One 0.5ml vial contains 50 mg of palivizumab. Palivizumab is a recombinant humanized monoclonal antibody produced by DNA technology in mouse myeloma host cells. •ATC group: J06BD01•Pharmaceutical form: injection solution•Required number: 2700 packages = injection vials Order type: Goods4.1.3 Scope of procurement Expected valueEstimated value (BT-27-Procedure) (value): 792 747Estimated value (BT-27-Procedure) (currency): EuroMain classificationType of classification: Common procurement vocabularyMain CPV code: Immune vaccines and immunoglobulinsInformation on additional classification of the subject of the contractInformation on the additional classification of the subject of the contract Classification type: Common procurement vocabulary4.1.4 Information about the place of fulfillment reasons for exclusionForm of publication of reasons for exclusion: Competition documents4.3 Information about the procedure4.3.1 ProcedureType of procedure: Public competition5. Parts 5.1 Information about part 5.1.1 Part Name: Palivizumab Purpose Description of part Reference number: 621/2025/VO/KB Name : Palivizumab Description: The subject of the contract is a human drug with the name Palivizumab for the planned procurement period of 36 months. Medical-technical specification of the subject of the order - Palivizumab 50mg/0.5ml: • Item type: Human drug • Drug + concentration: One 0.5ml vial contains 50 mg of palivizumab. Palivizumab is recombinant humanized a monoclonal antibody produced by DNA technology in mouse myeloma host cells. •ATC group: J06BD01•Pharmaceutical form: injection solution•Required number:...
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINPalivizumab Description: the Subject of the Order is a Human Medicine Called Palivizumab for the Planned Procurement Period of 36 Months. Medical and Technical Specification of the Subject of the Order Palivizumab 50Mg/0.5Ml: • Type Of... - Slovakia Tender
The NATIONAL INSTITUTE OF HEART AND VASCULAR DISEASES, A.S., a Government sector organization in Slovakia, has announced a new tender for Palivizumab Description: the Subject of the Order is a Human Medicine Called Palivizumab for the Planned Procurement Period of 36 Months. Medical and Technical Specification of the Subject of the Order Palivizumab 50Mg/0.5Ml: • Type Of.... This tender is published on SlovakiaTenders under SKT Ref No: 130303041 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-12-15.
The estimated tender value is EUR 792747, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
